Squamous Cell Carcinoma of the Skin Clinical Trial
Official title:
Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)
Status | Recruiting |
Enrollment | 61 |
Est. completion date | December 2027 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Men and women, 18 years of age and older on day of signing written informed consent 2. Histologically or cytologically documented locally-advanced and/or metastatic squamous cell carcinoma of the skin (stage III/IV AJCC 2010) that is incurable 3. Archival tumor tissue available for evaluation of PD-L1 and LAG-3 expression 4. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 5. Life expectancy of at least 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2 7. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration: - WBC = 2000/µl - Neutrophils = 1500/µL - Platelets = 100 x103/µL - Hemoglobin > 9.0 g/dL - Serum creatinine = 1.5 x ULN or creatinine clearance (CrCl) = 40 mL/min (if using the Cockcroft-Gault formula below): Female CrCl = (140 - age in years) x weight in kg x 0.85/72 x serum creatinine in mg/dL Male CrCl = (140- age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL - AST/ALT = 3 x ULN - Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) - Negative pregnancy test and effective contraception (Pearl-Index <1) for for women of childbearing potential (WOCBP) if the risk of conception exists 8. Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration 9. Prior systemic antibiotic treatment must have been completed at least 30 days prior to stool sample collection Exclusion Criteria: 1. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment 2. Prior therapy with CTLA-4, PD-1 or LAG-3 antibodies 3. History of myocarditis, regardless of etiology 4. Troponin T (TnT) or I (TnI) > 2× institutional upper limit of normal (ULN). Participants with TnT or TnI levels between > 1× to 2× ULN will be permitted if repeat levels within 24 hours are = 1× ULN. If TnT or TnI levels are between > 1× to 2× ULN within 24 hours, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are < 2× ULN, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator 5. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease 6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis 7. Known additional malignancy that is progressing or requires active treatment. Patients with chronic lymphocytic leukemia that is stable under active therapy are eligible for inclusion. 8. An active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger 9. Patients with serious intercurrent illness, requiring hospitalization 10. Other serious illnesses, e.g. serious infections requiring antibiotics 11. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial 12. Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25 IU/L or equivalent units of HCG)) or lactation period 13. Women of childbearing potential (WOCBP): Refusal or inability to use effective means of contraception (Pearl-Index <1) 14. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) 15. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection 16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator 17. Known hypersensitivity reaction to any of the components of study treatment |
Country | Name | City | State |
---|---|---|---|
Austria | Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie | Graz | |
Austria | LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie | Innsbruck | |
Austria | Klinikum Klagenfurt am Wörthersee | Klagenfurt | |
Austria | Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg | Salzburg | |
Austria | Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften | St.Pölten | |
Austria | Med Uni Wien, Univ. Klinik für Dermatologie | Vienna | |
Austria | Klinikum Wels-Grieskirchen GmbH | Wels |
Lead Sponsor | Collaborator |
---|---|
Salzburger Landeskliniken | Bristol-Myers Squibb |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) | using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment | up to 5 years | |
Secondary | Disease Control Rate (DCR) | Disease Control Rate (DCR) using Response Criteria in Solid Tumors version 1.1 (RECIST1.1) per site assessment | up to 5 years | |
Secondary | Duration of Response (DOR) in patients who achieve partial response (PR) or better | up to 5 years | ||
Secondary | Progression Free Survival (PFS) | up to 5 years | ||
Secondary | Overall Survival (OS) | up to 5 years | ||
Secondary | ORR and DCR for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells | up to 5 years | ||
Secondary | Number and severity of adverse events | up to 5 years | ||
Secondary | DOR, PFS and OS for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells | up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Active, not recruiting |
NCT06327971 -
Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
|
||
Not yet recruiting |
NCT03621462 -
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
|
N/A | |
Not yet recruiting |
NCT04480645 -
CivaDerm(TM) Surface Therapy Pilot Study
|
Early Phase 1 | |
Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
Recruiting |
NCT06014086 -
Intratumoral PH-762 for Cutaneous Carcinoma
|
Phase 1 | |
Completed |
NCT02347813 -
Preventing Squamous Cell Skin Cancer
|
Phase 2 | |
Terminated |
NCT01984892 -
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
|
Phase 2 | |
Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT03894618 -
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Terminated |
NCT01823679 -
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
Completed |
NCT00126555 -
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
Phase 2 | |
Completed |
NCT00089180 -
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
Phase 2 | |
Not yet recruiting |
NCT05246228 -
Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
|
||
Recruiting |
NCT05886140 -
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
|
N/A | |
Completed |
NCT02324608 -
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
|
N/A | |
Recruiting |
NCT02717936 -
Investigation of Desmoplastic Squamous Cell Carcinoma
|
N/A | |
Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
Withdrawn |
NCT01465815 -
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05490485 -
Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 2 |